• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

    3/1/22 8:35:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBRX alert in real time by email

    HOUSTON, March 1, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the appointment of Joy Yan, M.D., Ph.D. to its Board of Directors.

    Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)

    "We are incredibly pleased to welcome Dr. Yan to our Board of Directors. Her leadership and expertise in building, executing, and advancing clinical programs with major players in the pharma industry will be a valuable perspective as we work to progress our portfolio of drug candidates," added Walter Klemp, Chairman and CEO of Moleculin Biotech.

    Dr. Yan added, "I am excited to join the Moleculin Board of Directors and provide guidance to help position the Company for continued growth. This committed management team has made great accomplishments.  I believe that Moleculin's pipeline and science will propel the Company to its next development phase and build value for stakeholders."

    Joy Yan, M.D., Ph.D., currently serves as an Independent Board Director at Checkmate Pharmaceuticals. She is also a member of the Scientific Advisory Board at Ambrx, after her role as the Chief Medical Officer, where she led the pipeline strategy and quickly advanced the development programs. She also assisted on the cross-over financing and IPO. Previously at Bristol Myers Squibb,  she led the successful development of multiple oncology products from strategic planning through global submissions and approvals, including BMS' first FDA Pilot Programs (RTOR, Project ORBIS, AAid) for nivolumab and ipilimumab. She also has broad clinical development experience from her roles with Janssen and Bayer, where she led Phase 1, 2 and 3 studies exploring a variety of MOAs and evaluated NMEs (daratumumab, radium-223, anti-IL3R, Bi-specifics, ADCs, TKIs) across multiple tumor types.  

    Dr. Yan completed her Ph.D. in Biochemistry & Molecular Biology at Johns Hopkins University. She received her M.D. from China Medical University and completed her residency and clinical fellowship at University of Washington.

    About Moleculin Biotech, Inc.

    Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

    Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

    For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

    Forward-Looking Statements

    Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

    Investor Contact:

    JTC Team, LLC

    Jenene Thomas

    (833) 475-8247

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-announces-appointment-of-joy-yan-md-phd-to-board-of-directors-301492414.html

    SOURCE Moleculin Biotech, Inc.

    Get the next $MBRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MBRX

    DatePrice TargetRatingAnalyst
    2/12/2025Buy → Hold
    Maxim Group
    7/18/2022$14.00Outperform
    Oppenheimer
    More analyst ratings

    $MBRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

      Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON, Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the appointment of Daniel D. Von Hoff, M.D., F.A.C.P., FASCO, FAACR to its Annamycin Scientific Advisory Board. Walter Klemp, Chairman and Chief Executive Officer of Moleculin commented, "We are very pleased to welco

      11/4/24 8:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

      Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the treatment of acute myeloid leukemia (AML), Annamycin and the Company's AML clinical development program as well as data demonstrated to dateOngoing development progress of Annamycin toward pivotal AML study in 2024 with potential qualification for an accelerated approval pathwayHOUSTON, May 2, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will host a virtual AML Clinica

      5/2/24 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

      –     Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member HOUSTON, May 1, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman. Dr. Tallman is an internationally renowned clinical investigator whose discoveries have fueled the progress of leukemia-

      5/1/24 8:50:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yan Joy

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:06:10 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cermak Elizabeth

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:05:23 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Climaco John M

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      11/6/24 8:04:49 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    SEC Filings

    See more
    • Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/9/25 5:00:27 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/7/25 9:00:33 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Moleculin Biotech, Inc. (0001659617) (Filer)

      5/6/25 9:00:10 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      11/14/24 5:12:06 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Moleculin Biotech Inc.

      SC 13G - Moleculin Biotech, Inc. (0001659617) (Subject)

      2/14/24 3:43:13 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      2/10/21 11:28:21 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Foster Jonathan P. bought $20,000 worth of shares (28,986 units at $0.69), increasing direct ownership by 56% to 80,556 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:32:37 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • George Robert E. bought $10,000 worth of shares (14,493 units at $0.69), increasing direct ownership by 8,678% to 14,660 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:57 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Klemp Walter V bought $129,999 worth of shares (188,404 units at $0.69), increasing direct ownership by 38% to 680,880 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      12/27/23 7:31:05 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin

      Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin for the treatment of acute myeloid leukemia (AML); Interim data readout expected in the second half of 2025 HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organizat

      5/6/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

      Company continues to expand global IP coverage and claims to major markets, now extending to June 2040  HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the U.S. Patent and Trademark Office (USPTO) has granted two additional U.S. patents with claims covering Annamycin. U.S. patent number 12,257,261 titled, "Preparation of Preliposomal Annamycin Lyophilizate", has claims covering methods of making liposomal Annamycin and U.S. patent 12,257,262 titled "Method of Reconstituting Liposomal Anna

      5/5/25 8:45:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Moleculin Biotech downgraded by Maxim Group

      Maxim Group downgraded Moleculin Biotech from Buy to Hold

      2/12/25 8:44:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Moleculin Biotech with a new price target

      Oppenheimer resumed coverage of Moleculin Biotech with a rating of Outperform and set a new price target of $14.00

      7/18/22 9:16:10 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital resumed coverage on Moleculin Biotech

      Roth Capital resumed coverage of Moleculin Biotech with a rating of Buy

      2/1/21 4:03:54 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MBRX
    Financials

    Live finance-specific insights

    See more
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

      – Continued progress in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) toward first subject treated, on track to take place in the first quarter of 2025 – Multiple subjects currently being screened in first MIRACLE site activated – Initial data readout of the Phase 3 MIRACLE trial expected in the second half of 2025 – Company to host conference call and webcast today, Monday, March 24th at 8:30 AM ET HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported its financial results

      3/24/25 7:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

      HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the year ended December 31, 2024, on Friday afternoon, March 21, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Monday morning, March 24, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing t

      3/19/25 8:05:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care